12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersRezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago
Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Express News | HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Acurx Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 433.33% HC Wainwright & Co. $12 → $12 Reiterates Buy → Buy 03/19/2024 433.33% HC Wainwright & C
Buy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid Financials
Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...
Earnings Call Summary | Acurx Pharmaceuticals(ACXP.US) Q1 2024 Earnings Conference
The following is a summary of the Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript:Financial Performance:Acurx Pharmaceuticals ended Q1 2024 with a cash balance of $8.9 million, up
OPEN, BCRX and AWIN Among Pre-market Gainers
Express News | Acurx Pharmaceuticals Inc -Preparing to Submit Requests for Guidance to Initiate Clinical Trials in European Union, United Kingdom, Japan and Canada
Express News | Acurx Pharmaceuticals-Planning Continues to Advance Ibezapolstat Into International Phase 3 Clinical Trials for Treatment of C. Difficile Infection
Express News | Acurx Pharmaceuticals: Agreement Reached With FDA on Complete Non-Clinical and Clinical Development Plan for Filing of Nda for Marketing Approval
Express News | Acurx Pharmaceuticals Inc: Agreement With FDA Reached on Key Elements to Move Forward With Our International Phase 3 Clinical Trial Program
Express News | Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. Difficile Infection
Express News | Acurx Pharmaceuticals Q1 2024 GAAP EPS $(0.28) Misses $(0.24) Estimate
Express News | Acurx Pharmaceuticals Inc: Qtrly Shr Loss $0.28
Acurx Pharmaceuticals 1Q Loss $4.38M >ACXP
Acurx Pharmaceuticals 1Q Loss $4.38M >ACXP
Express News | Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
Express News | Acurx Pharmaceuticals Q1 Net Income USD -4.4 Million
Acurx Pharmaceuticals | 10-Q: Quarterly report
Express News | Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at Escmid Global 2024 Scientific Conference